ICU MEDICAL INC/DE Financials
Quarterly XBRL submissions from SEC 10-K and 10-Q filings.
Income Statement (Last 8 Quarters)
(3)| Period | Revenue | YoY % | Net Income | YoY % | Operating Income | EPS |
|---|---|---|---|---|---|---|
| Q3 FY202510-Q · 2025-09-30 | $537.0M | — | -$3.4M | — | $13.7M | -$0.14 |
| Q2 FY202510-Q · 2025-06-30 | $548.9M | — | $35.3M | — | $10.6M | $1.43 |
| Q1 FY202510-Q · 2025-03-31 | $604.7M | — | -$15.5M | — | $12.9M | -$0.63 |
Balance Sheet
| Period | Total Assets | Total Liabilities | Cash & Equivalents | Shareholders Equity |
|---|---|---|---|---|
| Q3 FY202510-Q | $4.1B | — | — | $2.1B |
| Q2 FY202510-Q | $4.1B | — | — | -$6.0K |
| Q1 FY202510-Q | $4.2B | — | — | -$60.0K |
Cash Flow Highlights
| Period | Operating Income | Net Income | Gross Profit | Shares Outstanding |
|---|---|---|---|---|
| Q3 FY202510-Q | $13.7M | -$3.4M | $200.9M | 24,686,000 |
| Q2 FY202510-Q | $10.6M | $35.3M | $208.1M | 24,685,000 |
| Q1 FY202510-Q | $12.9M | -$15.5M | $210.1M | 24,611,000 |
Filings
(4)Methodology
Every figure on this page is pulled directly from ICU MEDICAL INC/DE's own XBRL submissions to the U.S. Securities and Exchange Commission. XBRL is the standardized tagging format the SEC requires for line items in 10-K and 10-Q filings, which means revenue, net income, and balance-sheet entries are reported by the company itself — not estimated by us.
Cayman Journal reconciles preferred GAAP tags (for example, Revenues, RevenueFromContractWithCustomerExcludingAssessedTax) and normalizes them so quarter-over-quarter comparability is preserved. Our automated ingestion runs nightly; markets editors spot-check flagged anomalies before they appear on the public hub. Where a tag is missing for a given period, we surface an em dash rather than impute a value.
Source documents are linked under Filings above and point to the original EDGAR submission index. Errors should be reported to [email protected].